Patents by Inventor Mark Sutton

Mark Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidinone compounds which are HNE inhibitors
    Patent number: 9868740
    Abstract: This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: January 16, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • NOVEL COMPOUNDS
    Publication number: 20180009787
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • NOVEL COMPOUNDS
    Publication number: 20170340611
    Abstract: Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew HEALD, Andrew Stephen Robert JENNINGS, Carmelida CAPALDI, Elisabetta ARMANI
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9828382
    Abstract: Pyrimidone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and condition in which HNE is implicated.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 28, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Compounds
    Patent number: 9802919
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 31, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • NOVEL COMPOUNDS
    Publication number: 20170101413
    Abstract: This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
    Type: Application
    Filed: June 12, 2014
    Publication date: April 13, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian ALCARAZ, Robert Andrew HEALD, Jonathan Mark SUTTON, Elisabetta ARMANI, Carmelida CAPALDI
  • Covalently Linked Thermostable Kinase for Decontamination Process Validation
    Publication number: 20170052190
    Abstract: A biological process indicator is provided for validating a treatment process in which the amount or activity of a contaminant in a sample is reduced. The indicator comprises a thermostable kinase covalently linked to a biological component, with the proviso that the biological component is not an antibody. Methods of preparing the indicator, and methods of using the indicator, are also provided.
    Type: Application
    Filed: July 8, 2016
    Publication date: February 23, 2017
    Inventors: J. Mark Sutton, J. Richard Hesp, Michael Ungurs
  • Compounds
    Patent number: 9573955
    Abstract: Heterocyclic compounds and salts according to formula (I), which are pyrimidinone derivatives, described herein exhibit human neutrophil elastase inhibitory properties, and useful for treating diseases or conditions in which HNE is implicated.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: February 21, 2017
    Assignee: Chiese Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Compounds
    Patent number: 9487528
    Abstract: Compounds of formula (I), described herein, exhibit human neutrophil elastase inhibitory properties, and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 8, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi, Jonathan Mark Sutton, Robert Andrew Heald
  • NOVEL COMPOUNDS
    Publication number: 20160251362
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: LILIAN ALCARAZ, ROBERT ANDREW HEALD, JONATHAN MARK SUTTON, ELISABETTA ARMANI, CARMELIDA CAPALDI
  • Covalently linked thermostable kinase for decontamination process validation
    Patent number: 9416396
    Abstract: A biological process indicator is provided for validating a treatment process in which the amount or activity of a contaminant in a sample is reduced. The indicator comprises a thermostable kinase covalently linked to a biological component, with the proviso that the biological component is not an antibody. Methods of preparing the indicator, and methods of using the indicator, are also provided.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: August 16, 2016
    Assignee: The Secretary of State for Health
    Inventors: J. Mark Sutton, J. Richard Hesp, Michael Ungurs
  • Compounds
    Patent number: 9409870
    Abstract: Compounds of formula (I) described herein are imidazolone derivatives having human neutrophil elastase (HNE) inhibitory properties and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: August 9, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta Armani, Carmelida Capaldi, Jonathan Mark Sutton, Robert Andrew Heald
  • NOVEL COMPOUNDS
    Publication number: 20160168101
    Abstract: Compounds of formula (I) described herein are imidazolone derivatives having human neutrophil elastase (HNE) inhibitory properties and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: November 27, 2015
    Publication date: June 16, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisabetta ARMANI, Carmelida CAPALDI, Jonathan Mark SUTTON, Robert Andrew HEALD
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9365577
    Abstract: Pyrimidinone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HINE is implicated.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 14, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • NOVEL COMPOUNDS
    Publication number: 20150353561
    Abstract: Compounds of formula (I), described herein, exhibit human neutrophil elastase inhibitory properties, and are useful for the treatment of diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: June 5, 2015
    Publication date: December 10, 2015
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta ARMANI, Carmelida CAPALDI, Jonathan Mark SUTTON, Robert Andrew HEALD
  • Inhibition of enzymes
    Patent number: 9199984
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R5, R6, A1, A2, A3, A4 assume meanings as defined in formula (I) are inhibitors of neutrophil elastase.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: December 1, 2015
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Carmelida Capaldi, Robert Andrew Heald, Nicholas Charles Ray, Jonathan Mark Sutton
  • Biological indicator
    Patent number: 9102976
    Abstract: A kinase is used in a biological indicator for validation of treatment processes designed to reduce the amount or activity of a biological agent in a sample. The indication can be used for validation of sterilization treatment. The formation of ATP from a substrate comprising ADP is measured via the liciferin/luciferate system in a luminameter. Thermostable adenylate kinase from sulfolobus acidocaldarius is especially suitable for the validation of procedures to inactivate transmissable spongiform encephalopathy agents.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: August 11, 2015
    Assignee: The Secretary of State for Health
    Inventors: J. Mark Sutton, Neil David Hammond Raven
  • NOVEL COMPOUNDS
    Publication number: 20150166548
    Abstract: Heterocyclic compounds and salts according to formula (I), which are pyrimidinone derivatives, described herein exhibit human neutrophil elastase inhibitory properties, and useful for treating diseases or conditions in which HNE is implicated.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 18, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian ALCARAZ, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Lactate Production Process
    Publication number: 20150152449
    Abstract: A process for producing alkyl R-lactate from an initial compound comprising substructure (I) is provided. The process involves producing an intermediate comprising R,R- and S,S-lactide from the initial compound, wherein the initial compound is subjected to stereoisomerisation conditions; and reacting at least a portion of the intermediate with an alkyl alcohol to produce a product comprising alkyl R-lactate, wherein alkyl R-lactate is produced in the presence of an enzyme. Also provided are processes for the production of R-lactic acid, oligomeric R-lactic acid, R,R-lactide, poly-R-lactic acid and stereocomplex lactic acid.
    Type: Application
    Filed: June 10, 2013
    Publication date: June 4, 2015
    Inventors: Edward Leslie Marshall, Alan Keasey, David Mark Sutton
  • Compounds
    Patent number: 9023855
    Abstract: Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: May 5, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Toby Jonathan Blench, Christine Edwards, Robert Andrew Heald, Janusz Jozef Kulagowski, Jonathan Mark Sutton, Carmelida Capaldi